News
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)
Finalization of Vifor Pharma acquisition
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005796/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that
Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today issued a
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2022 financial results after the market
DGAP-News: Burcon JV, Merit Functional Foods Achieves Significant Innovation in a 100% Protein-based Solution to Replace Methylcellulose in Meat Alternatives
Valbiotis meldet den Abschluss der Rekrutierung für die klinische Phase II/III-Studie REVERSE-IT mit TOTUM•63 gegen Prädiabetes in Partnerschaft mit Nestlé Health Science
Valbiotis (FR0013254851 - ALVAL, PEA/KMU-qualifiziert) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Novocure Reports Second Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
Pfizer Inc. (NYSE: PFE) reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance
Valbiotis Announces Completion of Recruitment for the Phase II/III REVERSE-IT Clinical Study With TOTUM•63 Against Prediabetes, in Partnership With Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
ICON plc (NASDAQ: ICLR) ) (“ICON”), a world-leading healthcare intelligence and clinical research organisation, today announced that all resolutions at the Annual General Meeting of the Company
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
ICON Reports Second Quarter 2022 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2022.
CEO Dr. Steve
DGAP-Adhoc: MagForce AG: Provisional insolvency administrator appointed by the court
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating Fields Research Program
QIAGEN ergänzt digitales PCR-Portfolio QIAcuity um neue Biopharma-Produkte und führt Expert Custom Assay Design Service ein
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute mehrere Erweiterungen seiner Instrumente für digitalen PCR (dPCR) der QIAcuity-Serie bekannt. Mit den Neuerungen soll der Einsatz des
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers